HomeInnovation and DevelopmentR&D and Innovation
14
No.1 in Domestic Market
Share (from IQVIA data)
70
+New Development Projects
18
Products with Annual Sales
Exceeding 100 Million RMB
10
+Innovative Drugs
10
+Consistency Evaluation Products
220
+Authorized Patents
R&D and Innovation
Based on efficient and high-quality R&D, Wanbang Biopharma is continuously committed to develop "affordable innovation" and addressing unmet disease treatment need. Wanbang Biopharma invests exceed 10% of the annual sales revenues for drug research and development. In 2019, R&D investment increased by 92% year on year growth and continues to grow.
Scientific Research Achievements
At present, Wanbang Biophrma R&D pipeline has 72 projects which include 13 innovative drugs, 13 biosimilars and 21 consistency evaluation projects. Wanbang owns more than 220 patents, including 5 PCT patents, chaired in establishing 30 national standards.
Ranking
27
Ranked in the top 100 new drug applications of drug think tanks
50+
More Than 40 National Patent Applications Annually
10+
National, Provincial and Ministerial Research Projects
Clinical trials are under way for several innovative drugs, generics and biologics. In the consistency evaluation project of generic drugs, many products are in the leading position.10+ products have passed the Quality Consistency Evaluation for Generic Drugs.
The Youlitong (Febuxostat Tablet), type 3.1 new drug application, approved in 2013, has become the key product of Wanbang Biopharma.
Youlitong
Generic Name: Febuxostat Tablet
Two R&D Platforms
Biological Drug R&D Platform
Chemical Drug R&D Platform
International First-class Innovation Platform
- Postdoctoral Workstation
- Jiangsu Key R&D Enterprise Institutions
- Jiangsu Academician Workstation
- Jiangsu Recombinant Protein Drug Engineering Center
- Jiangsu Enterprise Technology Center
- Jiangsu Engineering Research Center for Diabetic Drugs
- Jiangsu Strategic Emerging Industry Innovation Demonstration Enterprise
- Top 100 Comprehensive Strengths of China's Chemical and Pharmaceutical Industrial Enterprises in 2019（27th）
R&D Team
Nearly 400
R&D Personnel
Nearly
7.9%
Proportion of R&D Personnel
In the Total Number of Employees
52%
Proportion of Senior Researchers
With Master/PhD Degrees
